Capital
R3i deploys and connects capital selectively where frontier technology, structural scarcity and credible institutional pathways converge.
Our investment work is informed by the same discipline as our transaction work: establish what is owned, what is proven, what remains uncertain and what must be true for value to compound.
01 · Investment lens
We look for assets that remain difficult to reproduce as software, models and information become increasingly abundant — proprietary science, intellectual property, validated data, industrial capability, regulated workflows, infrastructure or privileged access to market.
Technical narrative is not enough. We look for proof proportionate to the underlying claim and the capital required to advance it.
The technology must ultimately become legible to customers, regulators, strategic partners and future capital.
The structure, duration and expectations of capital must match the actual development pathway.
02 · Areas of attention
The same three domains govern transaction work and capital work. Sector boundaries matter less than whether the asset is scarce, defensible and capable of becoming institutionally executable.
Regulated AI · advanced compute · autonomy · defence
Energy · water · industrial infrastructure · critical materials
Health · life sciences
03 · Where we sit in the lifecycle
R3i is not confined to a single point in a company's life. The same evidentiary discipline applies at every stage — only the question changes.
Seed and Series A capital into scarce, defensible science, where the test is whether the claim can be proven at all.
Follow-on capital and pre-IPO secondaries into defence and regulated-AI companies that have proven the claim and are now proving the market.
Structured funding for pre-commercial research through the Future Intelligence Lab and Planet43, where the deliverable is not yet a company but the evidence that one should exist.
The Lab
R3i also builds decision-intelligence companies for defence, resources and critical infrastructure through the R3i Future Intelligence Lab, its venture studio.
Funds and vehicles
Lab companies are formed and held through R3i and its authorised entities, including R3i Studio and R3i-managed vehicles, with related-party positions disclosed and subject to independent valuation review. Secondary and co-investment positions are taken through transaction-specific vehicles for eligible investors.
Vehicles are named, and their status stated, only in confidential offering documentation. Funds and SPVs, in the legal architecture →
04 · For allocators
Institutional and strategic capital relationships are developed around specific opportunities, vehicles and mandates rather than generic access. R3i’s focus is defence and regulated AI, including sovereign and pre-IPO secondaries, where regulatory and ownership review shape who can participate.
Depending on structure, investors may engage with R3i around:
Vehicles are named, and their status stated, only in confidential offering documentation. Nothing on this page is an offer of securities, and no vehicle is represented as open for subscription.
05 · Conflicts
R3i may act as originator, adviser, investor or vehicle sponsor. The applicable role and any related-party interest are disclosed by mandate, before terms are agreed. Fee arrangements are disclosed in priority order, not layered silently, and Investment Committee members recuse themselves from decisions in which they hold a personal or related-party interest.
A risk-based AML/KYC policy applies across all entities and is a precondition of any commitment. R3i does not accept client transaction capital into its operating-company accounts.